Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Biomerica (BMRA) over the last 13 years, with Q4 2025 value amounting to $30000.0.

  • Biomerica's Current Deferred Revenue fell 6470.59% to $30000.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $30000.0, marking a year-over-year decrease of 6470.59%. This contributed to the annual value of $55000.0 for FY2025, which is 3529.41% down from last year.
  • Latest data reveals that Biomerica reported Current Deferred Revenue of $30000.0 as of Q4 2025, which was down 6470.59% from $54000.0 recorded in Q3 2025.
  • In the past 5 years, Biomerica's Current Deferred Revenue ranged from a high of $3.2 million in Q1 2022 and a low of $30000.0 during Q4 2025
  • For the 5-year period, Biomerica's Current Deferred Revenue averaged around $380356.9, with its median value being $60000.0 (2023).
  • Per our database at Business Quant, Biomerica's Current Deferred Revenue plummeted by 9772.08% in 2022 and then soared by 4166.67% in 2024.
  • Biomerica's Current Deferred Revenue (Quarter) stood at $2.2 million in 2021, then crashed by 97.72% to $49013.0 in 2022, then rose by 22.42% to $60000.0 in 2023, then skyrocketed by 41.67% to $85000.0 in 2024, then plummeted by 64.71% to $30000.0 in 2025.
  • Its last three reported values are $30000.0 in Q4 2025, $54000.0 for Q3 2025, and $55000.0 during Q2 2025.